Sequoia Research Study
A trial for a new medication to manage blood pressure in MSA is recruiting eligible participants.
MSA affects the autonomic system which can cause dizziness, light-headedness or fainting when standing up, changing position or being on your feet for a long period of time. This sudden drop in blood pressure is called neurogenic orthostatic hypotension (nOH).
Biotech company, Theravance Biopharma, are investigating the potential of a new drug for nOH.
Ampreloxetine has already been shown to be safe in healthy volunteers and in people that experience symptoms of nOH. Now, a phase 3 trial hopes to show benefits in a larger number of people with MSA, Parkinsons Disease and Pure Autonomic Failure.
The trial is running in the United States of America and across Europe. The UK research sites are in Birmingham, Plymouth, Exeter and London.
Half of the people taking part will receive the trial medication and the other half will receive a placebo. The results of both groups will be compared to see if the experimental new medication has a beneficial effect over the placebo group.
If this trial is shown to be beneficial it could result in this treatment becoming available across the UK, which will greatly improve the quality of lives for those affected by this symptom of neurogenic orthostatic hypotension.
Dr. Katherine Fletcher explains the trial further in this blog https://medium.com/parkinsons-uk/investigating-a-new-treatment-for-sudden-drops-in-blood-pressure-32ba31f05ff5.
Please visit our research page if you are interested in finding out more and taking part – https://www.msatrust.org.uk/cause-and-cure/current-research-opportunities-2/#tab2.
Disclaimer: The views and opinions expressed in the blogs published on these pages are those of the authors and do not necessarily reflect the official policy or position of the MSA Trust.
